Results 171 to 180 of about 6,314,192 (308)

A Standard of Care

Annals of Global Health, 2017
openaire   +4 more sources

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

Molecular Oncology, EarlyView.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor, Julio Celis, Ulrik Ringborg   +2 more
wiley   +1 more source

Standard of care for children and adolescents with chronic kidney disease and its Peculiarities: a call to action! [PDF]

J Bras Nefrol
Palma LMP, Penido MGMG, Soeiro EMD, Tavares MS, Garcia CD, Kaufman A, Greggi de Alcantara SA, Braga de Andrade OV, Zuntini KLDCR, Sobral RML, Carla de Souza V, Bernardes RP, Cristina de Andrade M, Bresolin NL, Nogueira PCK, Koch VHK.   +15 more
europepmc   +1 more source

Moving Toward an International Standard in Informed Consent: The Impact of Intersexuality and the Internet on the Standard of Care [PDF]

, 2002
Martin, Patricia L.
core   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Medulloblastoma: Current Standard of Care and Future Treatment Opportunities. [PDF]

Paediatr Drugs
Mayr L, Azizi AA, Gojo J, Peyrl A.
europepmc   +1 more source

Standard of Care [PDF]

Medico-Legal Journal, 1982
openaire   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Comparing polysomnography auto scoring with the standard of care in sleep medicine. [PDF]

Ann Thorac Med
Alhejaili F.
europepmc   +1 more source